NZ334941A - Methods for treating infections using proteins which induce an immune response in one animal species but not in another - Google Patents
Methods for treating infections using proteins which induce an immune response in one animal species but not in anotherInfo
- Publication number
- NZ334941A NZ334941A NZ334941A NZ33494197A NZ334941A NZ 334941 A NZ334941 A NZ 334941A NZ 334941 A NZ334941 A NZ 334941A NZ 33494197 A NZ33494197 A NZ 33494197A NZ 334941 A NZ334941 A NZ 334941A
- Authority
- NZ
- New Zealand
- Prior art keywords
- proteins
- antisera
- antibodies
- hiv
- human
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title abstract 4
- 230000028993 immune response Effects 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 abstract 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 abstract 1
- 102100034343 Integrase Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 abstract 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 abstract 1
- 238000002967 competitive immunoassay Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 239000006166 lysate Substances 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000004043 responsiveness Effects 0.000 abstract 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/5555—Muramyl dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ507680A NZ507680A (en) | 1996-10-10 | 1997-10-10 | Immunomodulators and carriers for immunogenic peptides comprising multiple repeats of muramyl dipeptide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2819496P | 1996-10-10 | 1996-10-10 | |
PCT/US1997/018257 WO1998015658A1 (en) | 1996-10-10 | 1997-10-10 | Compositions and methods for treating viral infections |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ334941A true NZ334941A (en) | 2000-11-24 |
Family
ID=21842081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ334941A NZ334941A (en) | 1996-10-10 | 1997-10-10 | Methods for treating infections using proteins which induce an immune response in one animal species but not in another |
Country Status (12)
Country | Link |
---|---|
US (6) | US6043347A (xx) |
EP (1) | EP0939835A4 (xx) |
JP (2) | JP2001502315A (xx) |
KR (2) | KR100667121B1 (xx) |
CN (1) | CN1327896C (xx) |
AU (1) | AU732809B2 (xx) |
BR (1) | BR9712289A (xx) |
CA (1) | CA2268372C (xx) |
HK (1) | HK1023371A1 (xx) |
MX (1) | MXPA02010374A (xx) |
NZ (1) | NZ334941A (xx) |
WO (1) | WO1998015658A1 (xx) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100667121B1 (ko) * | 1996-10-10 | 2007-01-12 | 프로브 인터내쇼날 | 바이러스 감염증 치료를 위한 조성물 및 방법 |
US7157091B1 (en) * | 1999-06-18 | 2007-01-02 | Ludwig Institute For Cancer Research | MAGE-A1 peptides presented by HLA class II molecules |
US6599441B1 (en) * | 2000-07-18 | 2003-07-29 | Emerald Biostructures, Inc. | Crystallization solutions |
CN1339319A (zh) * | 2000-08-18 | 2002-03-13 | 清华大学 | 一种治疗艾滋病的药物及其制备方法 |
US6987184B2 (en) * | 2001-02-15 | 2006-01-17 | Signal Pharmaceuticals, Llc | Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related |
JP2007524609A (ja) * | 2003-04-10 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | コンフォメーションに関する変種のプロファイリング、抗体組成物 |
US7206991B2 (en) * | 2003-10-15 | 2007-04-17 | Lsi Logic Corporation | Method, apparatus and program for migrating between striped storage and parity striped storage |
US7311928B2 (en) * | 2003-12-09 | 2007-12-25 | Briant Burke | Topical compositions containing tea tree oil for treatment of viral lesions |
US7723063B2 (en) * | 2004-04-28 | 2010-05-25 | Intrinsic Lifesciences | Methods for measuring levels of bioactive human hepcidin |
US20060110405A1 (en) * | 2004-08-20 | 2006-05-25 | Buckheit Robert W Jr | Plasma or serum fraction for treatment and prevention of viral infections and related conditions |
MX2007008497A (es) * | 2005-01-13 | 2007-09-14 | Novartis Vaccines & Diagnostic | Ensayos inmunosorbentes enlazados a enzimas usando reactivos de peptidos especificos de prion. |
EP1855112A1 (en) * | 2006-05-10 | 2007-11-14 | Inserm | Method for the in vitro screening of compounds inhibiting production of infectious HIV-1 virions |
US8200520B2 (en) | 2007-10-03 | 2012-06-12 | International Business Machines Corporation | Methods, systems, and apparatuses for automated confirmations of meetings |
US9415061B2 (en) * | 2008-04-01 | 2016-08-16 | Innate Immunotherapeutics Limited | Compositions and methods for treatment of neoplastic disease |
CN103990120B (zh) * | 2008-04-01 | 2018-06-05 | 伊耐特免疫治疗有限公司 | 抗感染剂及其用途 |
NZ571665A (en) * | 2008-09-30 | 2011-01-28 | Innate Therapeutics Ltd | Compositions and methods for treatment of radiation exposure utilising cross-linked muramyl dipeptide microparticles |
EP2444414A4 (en) | 2009-05-18 | 2013-06-12 | Nat Univ Corp Tokyo Med & Dent | PEPTIDANTES FOR INDUCING ANTIBODIES FOR THE DETECTION OF THREE-DIMENSIONAL HIV STRUCTURES AND METHOD FOR THEIR SYNTHETIZATION |
NZ577731A (en) * | 2009-06-16 | 2010-08-27 | Innate Therapeutics Ltd | Compositions and methods for treatment of multiple sclerosis |
EP3187585A1 (en) | 2010-03-25 | 2017-07-05 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
RU2517084C2 (ru) * | 2010-08-06 | 2014-05-27 | Олег Ильич Эпштейн | Способ и средство для ингибирования продукции или усиления элиминации белка р24 |
CN103502264A (zh) | 2011-04-04 | 2014-01-08 | 国立大学法人东京医科齿科大学 | Hiv立体结构识别抗体诱导肽 |
PL2691530T3 (pl) | 2011-06-10 | 2019-02-28 | Oregon Health & Science University | Glikoproteiny i rekombinowane wektory CMV |
US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
AU2022208435A1 (en) | 2021-01-18 | 2023-08-10 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5528933A (en) * | 1978-08-21 | 1980-02-29 | Dai Ichi Seiyaku Co Ltd | Muramyldipeptide dimer |
CA1341423C (en) * | 1984-10-31 | 2003-03-04 | Paul A. Luciw | Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome |
US4946945A (en) * | 1987-06-23 | 1990-08-07 | Allergy Immuno Technologies, Inc. | Immunotherapy agents for treatment of IgE mediated allergies |
US5128319A (en) * | 1987-08-28 | 1992-07-07 | Board Of Regents, The University Of Texas System | Prophylaxis and therapy of acquired immunodeficiency syndrome |
CA2025634A1 (en) * | 1989-09-19 | 1991-03-20 | Thomas Fuerst | Peptides including ctl epitopes of hiv proteins and use thereof |
US6565842B1 (en) | 1995-06-07 | 2003-05-20 | American Bioscience, Inc. | Crosslinkable polypeptide compositions |
KR100667121B1 (ko) * | 1996-10-10 | 2007-01-12 | 프로브 인터내쇼날 | 바이러스 감염증 치료를 위한 조성물 및 방법 |
-
1997
- 1997-10-10 KR KR1020057016920A patent/KR100667121B1/ko not_active IP Right Cessation
- 1997-10-10 CN CNB971987432A patent/CN1327896C/zh not_active Expired - Lifetime
- 1997-10-10 WO PCT/US1997/018257 patent/WO1998015658A1/en not_active Application Discontinuation
- 1997-10-10 NZ NZ334941A patent/NZ334941A/xx not_active IP Right Cessation
- 1997-10-10 KR KR1019997003052A patent/KR100547049B1/ko not_active IP Right Cessation
- 1997-10-10 EP EP97910856A patent/EP0939835A4/en not_active Withdrawn
- 1997-10-10 US US08/948,782 patent/US6043347A/en not_active Expired - Lifetime
- 1997-10-10 CA CA2268372A patent/CA2268372C/en not_active Expired - Lifetime
- 1997-10-10 BR BR9712289-0A patent/BR9712289A/pt not_active Application Discontinuation
- 1997-10-10 MX MXPA02010374A patent/MXPA02010374A/es active IP Right Grant
- 1997-10-10 AU AU48131/97A patent/AU732809B2/en not_active Expired
- 1997-10-10 JP JP10517749A patent/JP2001502315A/ja not_active Ceased
-
2000
- 2000-01-14 US US09/482,612 patent/US6258599B1/en not_active Expired - Lifetime
- 2000-04-28 HK HK00102583A patent/HK1023371A1/xx not_active IP Right Cessation
- 2000-10-02 US US09/677,554 patent/US6335017B1/en not_active Expired - Lifetime
-
2001
- 2001-11-05 US US09/985,581 patent/US6670181B2/en not_active Expired - Lifetime
-
2003
- 2003-10-28 US US10/695,112 patent/US20040141996A1/en not_active Abandoned
-
2006
- 2006-11-28 US US11/605,017 patent/US8110203B2/en not_active Expired - Fee Related
-
2008
- 2008-10-06 JP JP2008259812A patent/JP2009080118A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2268372A1 (en) | 1998-04-16 |
AU4813197A (en) | 1998-05-05 |
US6043347A (en) | 2000-03-28 |
US20020086034A1 (en) | 2002-07-04 |
JP2001502315A (ja) | 2001-02-20 |
US20070154917A1 (en) | 2007-07-05 |
US6258599B1 (en) | 2001-07-10 |
KR20000048994A (ko) | 2000-07-25 |
EP0939835A1 (en) | 1999-09-08 |
MXPA02010374A (es) | 2003-04-25 |
CN1234078A (zh) | 1999-11-03 |
BR9712289A (pt) | 1999-08-31 |
WO1998015658A1 (en) | 1998-04-16 |
KR100667121B1 (ko) | 2007-01-12 |
US6335017B1 (en) | 2002-01-01 |
US20040141996A1 (en) | 2004-07-22 |
AU732809B2 (en) | 2001-05-03 |
CA2268372C (en) | 2012-11-27 |
KR100547049B1 (ko) | 2006-02-01 |
US6670181B2 (en) | 2003-12-30 |
KR20060041157A (ko) | 2006-05-11 |
JP2009080118A (ja) | 2009-04-16 |
HK1023371A1 (en) | 2000-09-08 |
US8110203B2 (en) | 2012-02-07 |
CN1327896C (zh) | 2007-07-25 |
EP0939835A4 (en) | 2004-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ334941A (en) | Methods for treating infections using proteins which induce an immune response in one animal species but not in another | |
Von Reyn et al. | Human immunodeficiency virus infection and routine childhood immunisation | |
Bishop et al. | Humoral immunity in experimental syphilis: I. The demonstration of resistance conferred by passive immunization | |
Sutton et al. | Post-immunisation gastritis and Helicobacterinfection in the mouse: a long term study | |
Zhang et al. | Longevity of Sm-p80-specific antibody responses following vaccination with Sm-p80 vaccine in mice and baboons and transplacental transfer of Sm-p80-specific antibodies in a baboon | |
Ganz et al. | Responses of patients with neoplastic diseases to influenza virus vaccine | |
Hirsch et al. | Effects of anti-thymocyte serum on Rauscher virus infection of mice | |
EP4226938A3 (en) | Coronavirus vaccine | |
Giordanengo et al. | Cruzipain induces autoimmune response against skeletal muscle and tissue damage in mice | |
WO2023147092A3 (en) | Coronavirus vaccine | |
Lang et al. | Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of post-exposure rabies vaccination under the 2-1-1 regimen: a field trial in Indonesia. MAS054 Clinical Investigator Group. | |
Bretscher et al. | Vaccination against and treatment of tuberculosis, the leishmaniases and AIDS: perspectives from basic immunology and immunity to chronic intracellular infections | |
Kempe et al. | Smallpox immunization in the United States | |
Gorse et al. | Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration | |
Shelke et al. | Equine rabies immunoglobulin: A review | |
Dezfulian et al. | Role of the mammary tumor virus in the immunogenicity of spontaneous mammary carcinomas of BALB/c mice and in the responsiveness of the hosts | |
Peckinpaugh et al. | Mass enteric live adenovirus vaccination during epidemic ARD | |
Shearer et al. | Alloantigen-based AIDS vaccine: revisiting a" rightfully" discarded promising strategy | |
Hunsmann et al. | Active immunization with feline leukemia virus envelope glycoprotein suppresses growth of virus-induced feline sarcoma | |
NO890565L (no) | Forhindring og behandling av retroviral sykdom. | |
Ter‐Grigorov et al. | The stimulating effect of complete Freund's adjuvant on tumour induction by polyoma virus in mice and by Rous sarcoma virus in rats | |
Hall et al. | Boosterable IgE antibody response in mice without the use of adjuvant | |
Haagensen Jr et al. | Immunologic control of the ascites form of murine adenocarcinoma 755. I. Protection with syngeneic immune serum or lymphoid cells | |
CHOW | Gonadotropins of the swine pituitary III. Immunological specificity of swine metakentrin | |
RU2145876C1 (ru) | Способ стимулирования иммунного ответа против паразитических гельминтов животных |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) | ||
ASS | Change of ownership |
Owner name: INNATE IMMUNOTHERAPEUTICS LIMITED, NZ Effective date: 20150522 |
|
EXPY | Patent expired |